Opt-IVF Improves Outcomes in Poor Responders by Enhancing Clinical Pregnancy Rates

The superovulation phase plays a crucial role in determining the success and cost-effectiveness of assisted reproductive technology (ART). Previous research has indicated that the clinical decision support tool Opt-IVF can optimize hormone dosing, leading to more high-quality embryos, reduced hormone requirements, and fewer ultrasound tests.

A recent retrospective, single-center cohort study evaluated whether Opt-IVF improves clinical pregnancy rates in real-world practice. Conducted over 24 months, the study included 204 women aged 25–45 who underwent superovulation using Opt-IVF-guided dosing (intervention group) and 207 women treated conventionally without the tool (control group).

Women in the Opt-IVF group required significantly lower cumulative gonadotropin doses and produced 20% more total embryos and 50% more high-quality embryos than those in the control group. Although the overall clinical pregnancy rate (including canceled cycles) was higher in the control group (45% vs. 35%), Opt-IVF demonstrated a marked advantage among older patients and poor responders.

The findings underscore Opt-IVF’s potential to enhance outcomes in challenging IVF cases. By personalizing hormone dosing, minimizing monitoring needs, and improving embryo yield, Opt-IVF offers a data-driven approach to improving pregnancy outcomes and advancing individualized reproductive care.

Source: Diwekar U, Joag S, Patel N, et al. Indian Obstetrics and Gynaecology. 2024 Jul 23;14(2).